Company / Free Cash Flow
Cullinan Therapeutics, Inc. Free Cash Flow History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$145.3M
FY2024
5-year range
-$145.3M / -$29.8M
FY2020-FY2024
Trend
-8.0%
vs FY2023
Sector context
#129 of 194
Health Care
What the data says
At -$145M, Cullinan Therapeutics, Inc.'s free cash flow ranks #129 of 194 in the Health Care sector. Free Cash Flow has declined for 3 consecutive years, from -$30M in FY2021 to -$145M in FY2024.
Based on SEC 10-K filings.
-$145M in FY2024.
Declined from -$128M to -$145M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#129 of 194 in Health CareTop 66% of 194This company -$145.3M Sector average $470.8M
▼
-130.9% below sector average
Key checks
Key Insights
- Cullinan Therapeutics, Inc.'s free cash flow has declined for 3 consecutive years.
- In FY2024, free cash flow decreased 8.0% year-over-year.
- Ranks #129 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.33 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$145.3M | -8.0% |
| FY2023 | -$134.5M | -5.2% |
| FY2022 | -$127.8M | -329.1% |
| FY2021 | -$29.8M | +0.0% |
| FY2020 | -$29.8M | - |
As of FY2024 · SEC 10-K · Updated Jul 2, 2026